ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Genetically Validated Immune Susceptibility Markers for Crohn's Disease: A Multi-Omics Mendelian Randomization Analysis.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crohn's disease (CD) is a chronic inflammatory bowel disorder with a multifactorial genetic, immune, and environmental basis, yet robustly validated therapeutic targets remain limited. We applied a multi-omics Mendelian randomization (MR) framework and colocalization to prioritize genetically supported immune susceptibility loci for CD. Methods: A two-sample MR framework was used, integrating protein quantitative trait loci (pQTL) and expression quantitative trait loci (eQTL) datasets with genome-wide association study (GWAS) data on CD from the Finnish biobank. After identifying 994 pQTL genes, 610 genes overlapping with known druggable targets were selected. Causal associations with CD were evaluated using inverse variance weighted (IVW) MR. Significant hits were further validated through colocalization analysis and summary-data-based Mendelian randomization (SMR). Results: IVW analysis identified 56 pQTL genes significantly associated with CD risk, with six genes (including Conclusion: These findings suggest that HLA-A represents a genetically validated immune susceptibility marker in CD. By integrating pQTL, eQTL, colocalization, and SMR analyses, it highlights the utility of multi-omics MR in uncovering novel genetic contributors to complex diseases. Further experimental and clinical validation is warranted to explore the translational potential of targeting
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.